| __timestamp | BioMarin Pharmaceutical Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 26684000 |
| Thursday, January 1, 2015 | 402271000 | 29829000 |
| Friday, January 1, 2016 | 476593000 | 39578000 |
| Sunday, January 1, 2017 | 554336000 | 43277000 |
| Monday, January 1, 2018 | 604353000 | 48645000 |
| Tuesday, January 1, 2019 | 680924000 | 52934000 |
| Wednesday, January 1, 2020 | 737669000 | 61349000 |
| Friday, January 1, 2021 | 759375000 | 127125000 |
| Saturday, January 1, 2022 | 854009000 | 136106000 |
| Sunday, January 1, 2023 | 937300000 | 133175999 |
| Monday, January 1, 2024 | 1009025000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of BioMarin Pharmaceutical Inc. and HUTCHMED (China) Limited from 2014 to 2023.
BioMarin has consistently outpaced HUTCHMED in SG&A spending, reflecting its expansive operational scale. Over the decade, BioMarin's SG&A expenses surged by approximately 210%, peaking in 2023. In contrast, HUTCHMED's expenses grew by nearly 400%, albeit from a smaller base, indicating aggressive expansion strategies.
This financial trajectory highlights BioMarin's established market presence and HUTCHMED's rapid growth ambitions. Investors and industry analysts can glean insights into each company's strategic priorities and market positioning through these financial patterns.
Eli Lilly and Company or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Pfizer Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Opthea Limited Trends and Insights
BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs HUTCHMED (China) Limited Trends and Insights
Axsome Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
CymaBay Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Amicus Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: HUTCHMED (China) Limited vs Novavax, Inc.